We are monitoring the impact of COVID-19 on North America Clinical Trials Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1576
Share on
Share on

North America Clinical Trials Market Analysis – Segmented By Phase, Design, Indications, By Country (United States, Canada and Rest of North America) - Industry Analysis, Size, Share, Growth, Trends, & Forecast | 2020 - 2025

Pulished: February, 2020
ID: 1576
Pages: 145

As per our report, the North American Clinical Trials Market size has been estimated at USD 5.65 billion in 2020 and is projected to reach USD 8.08 billion by 2025 at a CAGR of 7.40% during the forecast period from 2020 to 2025. North America market is accredited with increasing R&D and also increasing the new technologies in clinical research. These factors are anticipated to boost the regional market growth. Within North America, the United States Clinical Trials Market size is expected to grow at a healthy rate in the coming years.

Throughout emerging nations, due to the growing prevalence of infectious and tropical diseases in the world, there are various unmet needs for clinical trials for new drugs. It is observed that the population has a diverse disease profile that increases over time, which is expected to improve clinical trials for new or rare diseases. The number of patients with a specific disease would, therefore, serve as a catalyst to spend more in clinical trials for a disease category of biopharmaceutical companies.

The market to show rapid growth due to emerging market demand for clinical trials, high pharmaceutical industry R&D spending, and increasing disease prevalence.  For Instance, The National Clinical Trials Registry (NCT) Says, in 2020 there are around 11,865 active clinical trials carried across different phases for cancer indication in the United States.

Healthcare systems are witnessing tectonic shifts as well as seeing a huge inflow of new models of clinical trials being coordinated, standardized, and patient interest nurtured. Pharmaceutical companies ' expenditure on research and development (R&D) has already rapidly increased over the past few years. This is mainly due to several patent expiries because prior to the expiry of the patent, there are several pharmaceutical companies that will have no choice but to come up with new medicines. The firms are therefore to invest more in R&D to boost drug development through clinical trials and henceforth increase the overall demand. It is anticipated that strategic partnerships between pharmaceutical companies and CROs will have a huge impact on the growth of the sector.

Factors like lack of skilled clinical research in the workforce, poor reimbursement for health care in developing nations, and strict patient enrolment regulations, however, hamper the market growth. Many companies outsource their recently developed drug clinical trials to different contract research organizations as it could save them from the research and development process the hassles of regulatory issues and the expense of patient recruitment.

This report has been segmented into the following categories:

  • By Phase: Phase I, Phase II and Phase III
  • By Design: Interventional trials, Observational trials and Expanded Access trials
  • By Indications: Autoimmune, Blood disorders, Cancer, Circulatory, CNS, Congenital, CVS, Dermatology, Ear, Gastrointestinal, Genitourinary, Infections, Mental disorders, Metabolic, Musculoskeletal, Nose and Ophthalmology  
  • By Country: the United States, Canada and Rest of North America

Geographically, North America is the biggest market in terms of market share across the globe. Ample availability of funds to outsource clinical trials serves as the major growth driver for North America.

North America is leading the market in 2019 and also expected to lead in the future. The U.S. Clinical Trials Market is holding the largest shares of the market. Adoption of technological developments is levelling up the demand of the market. North America conducts a number of clinical trials spend the highest funds with USD 753.7 million given by the National Institute of Health (NHI) in 2018 which was the highest healthcare per capita. Canada Clinical Trials Market size is expected to grow more in Phase-III by 2027.

Companies playing a key role in the market profiled in this report are Chiltern, Omnicare, PPD, Parexel, Kendle, Quintiles, ICON Plc, and Charles River. Most companies are outsourcing the clinical trials of their newly developed drugs to various contract research organizations as this could save them the hassles of regulatory issues and patient recruitment burden from the research and development phase.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods  

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Phases                          

                                5.1.1 Introduction           

                                5.1.2 Phase I      

                                5.1.3 Phase II    

                                5.1.4 Phase III   

                                5.1.5  Y-o-Y Growth Analysis, By Phases                

                                5.1.6  Market Attractiveness Analysis, By Phases              

                                5.1.7  Market Share Analysis, By Phases                

                5.2 Design                          

                                5.2.1 Introduction           

                                5.2.2 Interventional trials             

                                5.2.3 Observational trials             

                                5.2.4 Expanded Access trials       

                                5.2.5  Y-o-Y Growth Analysis, By Design 

                                5.2.6  Market Attractiveness Analysis, By Design               

                                5.2.7  Market Share Analysis, By Design

                5.3 Indications                  

                                5.3.1 Introduction           

                                5.3.2 Autoimmune         

                                5.3.3 Blood disorders     

                                5.3.4 Cancer      

                                5.3.5 Circulatory               

                                5.3.6 CNS            

                                5.3.7 Congenital               

                                5.3.8 CVS            

                                5.3.9 Dermatology          

                                5.3.10 Ear            

                                5.3.11 Gastrointestinal  

                                5.3.12 Genitourinary      

                                5.3.13 Infections              

                                5.3.14 Mental disorders

                                5.3.15 Metabolic              

                                5.3.16 Musculoskeletal 

                                5.3.17 Nose       

                                5.3.18 Ophthalmology   

                                5.3.19  Y-o-Y Growth Analysis, By Indications      

                                5.3.20  Market Attractiveness Analysis, By Indications    

                                5.3.21  Market Share Analysis, By Indications      

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Phase

                                                6.1.3.3 By Design

                                                6.1.3.4 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Phase

                                                6.1.4.3 By Design

                                                6.1.4.4 By Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Phase

                                                6.1.5.3 By Design

                                                6.1.5.4 By Indication

                6.2 United States                            

                6.3 Canada                         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Chiltern                        

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Omnicare                    

                8.3 PPD                

                8.4 Parexel                         

                8.5 Kendle                          

                8.6 Quintles                       

                8.7 ICON Plc                       

                8.8 Charles River                              

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Clinical Trial Market By Phase, From 2020 - 2025 ( USD Billion )
  2. North America Phase I Market By Region, From 2020 - 2025 ( USD Billion )
  3. North America Phase II Market By Region, From 2020 - 2025 ( USD Billion )
  4. North America Phase III Market By Region, From 2020 - 2025 ( USD Billion )
  5. North America Clinical Trial Market By Design, From 2020 - 2025 ( USD Billion )
  6. North America Interventional trials Market By Region, From 2020 - 2025 ( USD Billion )
  7. North America Observational trials Market By Region, From 2020 - 2025 ( USD Billion )
  8. North America Expanded Access trials Market By Region, From 2020 - 2025 ( USD Billion )
  9. North America Clinical Trial Market By Indications, From 2020 - 2025 ( USD Billion )
  10. North America Autoimmune Market By Region, From 2020 - 2025 ( USD Billion )
  11. North America Blood disorders Market By Region, From 2020 - 2025 ( USD Billion )
  12. North America Cancer Market By Region, From 2020 - 2025 ( USD Billion )
  13. North America Circulatory Market By Region, From 2020 - 2025 ( USD Billion )
  14. North America CNS Market By Region, From 2020 - 2025 ( USD Billion )
  15. North America Congenital Market By Region, From 2020 - 2025 ( USD Billion )
  16. North America CVS Market By Region, From 2020 - 2025 ( USD Billion )
  17. North America Dermatology Market By Region, From 2020 - 2025 ( USD Billion )
  18. North America Ear Market By Region, From 2020 - 2025 ( USD Billion )
  19. North America Gastrointestinal Market By Region, From 2020 - 2025 ( USD Billion )
  20. North America Genitourinary Market By Region, From 2020 - 2025 ( USD Billion )
  21. North America Infections Market By Region, From 2020 - 2025 ( USD Billion )
  22. North America Mental disorders Market By Region, From 2020 - 2025 ( USD Billion )
  23. North America Metabolic Market By Region, From 2020 - 2025 ( USD Billion )
  24. North America Musculoskeletal Market By Region, From 2020 - 2025 ( USD Billion )
  25. North America Nose Market By Region, From 2020 - 2025 ( USD Billion )
  26. North America Ophthalmology Market By Region, From 2020 - 2025 ( USD Billion )
  27. United States Clinical Trial Market By Phase, From 2020 - 2025 ( USD Billion )
  28. United States Clinical Trial Market By Design, From 2020 - 2025 ( USD Billion )
  29. United States Clinical Trial Market By Indications, From 2020 - 2025 ( USD Billion )
  30. Canada Clinical Trial Market By Phase, From 2020 - 2025 ( USD Billion )
  31. Canada Clinical Trial Market By Design, From 2020 - 2025 ( USD Billion )
  32. Canada Clinical Trial Market By Indications, From 2020 - 2025 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample